Prediction Open AI assessment confidence: 95% certainty 3/5 debate potential 1/5

Hodak: Science's in-house retinal gene therapy probably enters human trials next year

Max Hodak · From Restoring Sight to Reimagining the Brain, with Max Hodak · Aug 20, 2026 · at 4:40

Max Hodak, CEO of Science Corporation and former Neuralink president, discusses the development timeline of their indigenous retinal gene therapy platform.

0:00 / 0:05exact quote · 5.6s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“What we ended up doing is we developed indigenously a state of the art gene therapy, which is probably going to humans next year.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Science Corporation's internally developed retinal gene therapy will begin human clinical trials or administration by the end of 2027.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

On August 20, 2026, then-CEO Max Hodak stated that Science Corporation's internally developed retinal gene therapy would likely begin human administration in 2027 ('probably going to humans next year', establishing a stated horizon through December 31, 2027). As of September 3, 2026, public clinical trial registries (including ClinicalTrials.gov and EU CTIS) reflect no registered interventional clinical trials or first-in-human administrations for Science Corporation's proprietary optogenetic gene therapy (Science Eye). While Science Corporation operates clinical trials for the PRIMA retinal implant, PRIMA is an acquired photovoltaic technology rather than the in-house gene therapy referenced. Because the stated horizon of December 31, 2027 has not yet arrived and trial initiation remains pending, the claim cannot yet be determined.

As of September 2026, no clinical trial registry records exist for Science Corporation's in-house optogenetic gene therapy (Science Eye).
Science Corporation's active clinical trial (NCT04676854) pertains to the PRIMA photovoltaic subretinal implant acquired from Pixium Vision in April 2024, not the internally developed retinal gene therapy.
The stated deadline for entering human clinical trials is December 31, 2027, which remains in the future relative to the assessment date of September 3, 2026.

Checked against

[1] medtechdive.com [2] bionic-vision.org [3] science.xyz [4] science.xyz [5] science.xyz [6] market-scope.com [7] science.xyz [8] market-scope.com

"Science Eye" "optogenetic" "Max Hodak" "Science Corporation" "Science Eye" clinical trial status 2025 OR 2026 Science Corporation retinal gene therapy clinical trial "Science Eye" "gene therapy" clinical trial Science Corporation Science Eye PRIMA Pixium Vision clinical trial

assessed as of 2026-09-03

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

⏳ prediction date: 2027-12-31; checked again automatically on the next resolution wave

Mentioned

gene therapy Science

⚑ Spot an error? Report it

More from Max Hodak

Assertion Contradicted

Hodak: Science is the first to restore form vision in blind patients

“Nobody had previously ever been able to restore a form vision image in the mind's eye of a blind patient in this way.”

Max Hodak Aug 20, 2026 ▶ 8:44 From Restoring Sight to Reimagining the Brain, with Max Hodak

Insight

Hodak: Vision, hearing, balance, and 1 kbps motor control unlock radical neurotech

“If you can, if you get vision, hearing, balance, and a kilobit per second of motor control, you're halfway to the matrix. And this takes you into some like really trippy interpret reinterpretations of medicine.”

Max Hodak Aug 20, 2026 ▶ 14:06 From Restoring Sight to Reimagining the Brain, with Max Hodak

Assertion Open · timeframe Aug 2029

Hodak: Science aligns animal brain recordings with AI model representations

“We use that constructively at science like that. So we know that that is. That is true because we can get alignments between animal brain neural recordings and AI model internal representations.”

Max Hodak Aug 20, 2026 ▶ 20:40 From Restoring Sight to Reimagining the Brain, with Max Hodak

Prediction Not checkable as stated

Hodak: Cardiovascular disease and non-brain cancer are attackable via organ replacement

“The two leading causes of death though, are cardiovascular disease and cancer is not metastasized to the brain. And I think both of those are going to be really attackable through this type of work.”

Max Hodak Aug 20, 2026 ▶ 28:17 From Restoring Sight to Reimagining the Brain, with Max Hodak

Insight

Hodak: The brain and the universe are literally physical computers

“I mean, to me, I don't mean that metaphorically, like the brain very literally, very clearly, plainly is a computer in, in my understanding of the world. I also view the universe generally as a computer. Like we can solve pro like you can solve computational p…”

Max Hodak Aug 20, 2026 ▶ 10:12 From Restoring Sight to Reimagining the Brain, with Max Hodak

Opinion

Hodak: Most people will not accept digital brain replicas as survival

“If I could make a copy of you, and you can talk to that copy, and you're like, okay, I will go away now. I just don't think that many people are going to be like, this is it.”

Max Hodak Aug 20, 2026 ▶ 16:58 From Restoring Sight to Reimagining the Brain, with Max Hodak

Hodak: Science's in-house retinal gene therapy probably enters human trials next year

More from Max Hodak

Turn any episode into a week of clips.